HomeCompoundsTesamorelin
GHRH analogueRx · FDA approved

Tesamorelin.

Also known as: Egrifta · TH9507

Why visceral fat responds best, the FDA-approved indication, off-label use, and how to source it legally.

EP
Researched and edited by the Epti editorial team
Every claim labeled by confidence tier · reviewed quarterly · last updated May 20, 2026
01 · Quick Overview

Quick Overview.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete endogenous growth hormone. It is the only GHRH analogue that is FDA-approved (under the brand name Egrifta) specifically for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. [2]

Unlike exogenous human growth hormone (hGH), which replaces the body's natural production and can suppress pituitary function, tesamorelin works by amplifying the body's natural pulsatile release of GH. [3] It is widely considered the most potent GHRH analogue available for targeted visceral fat reduction, though it is also the most expensive. [4]

Who it is for:

  • Individuals seeking targeted reduction of visceral (abdominal) fat.
  • Those looking to improve lipid profiles (triglycerides and cholesterol) associated with central adiposity.
  • Patients with HIV-associated lipodystrophy (its on-label use).

Who it is NOT for:

  • Individuals looking for rapid, massive muscle hypertrophy (it is not an anabolic steroid).
  • Those with active malignancies or a history of cancer.
  • Tested athletes (it is banned by WADA).
epti
Track your protocol

Turn this protocol into your actual schedule.

Log every dose, every side-effect, and every PR on one timeline.

Join waitlist →
02 · The Protocol & Usage Guide

The Protocol & Usage Guide.

Before You Start: The Checklist

  • Baseline Bloodwork: Fasting glucose, HbA1c, IGF-1, lipid panel, and liver enzymes.
  • Supplies: Insulin syringes (typically 31G, 5/16"), bacteriostatic water, alcohol swabs.
  • Storage: Must be refrigerated (2°C to 8°C) after reconstitution.

Standard Dosing Protocols

Experience LevelDoseFrequencyNotes
FDA Approved (Egrifta)2 mgDailyAdministered subcutaneously. [2]
Community Standard1 mgDailyOften stacked with an Ipamorelin. community
Advanced2 mgDailySplit into two 1 mg doses (morning/night). community

Note: The FDA-approved dose is 2 mg daily, but the community consensus for anti-aging and body composition is typically 1 mg daily due to cost and efficacy at lower doses when stacked. community

Injection Timing & Fasting

Tesamorelin must be administered on an empty stomach to prevent insulin and somatostatin from blunting the GH pulse.

  • Nighttime Protocol: Inject right before bed, at least 2 hours after the last meal.
  • Morning Protocol: Inject immediately upon waking, wait at least 30-60 minutes before consuming calories.

Cycle Length

  • Standard Cycle: 12 to 16 weeks. community
  • Time Off: 4 to 8 weeks off between cycles to prevent receptor downregulation. community

Missed Dose Protocol

If a dose is missed, skip it and resume the normal schedule the next day. Do not double the dose to make up for a missed one.

04 · Safety, Interactions & Side Effect Management

Safety, Interactions & Side Effect Management.

Side Effect Profile

Side EffectSeverityFrequencyManagement
Injection site reactions (erythema, pruritus)MildCommonRotate injection sites daily.
Arthralgia (joint pain) / MyalgiaMild to ModerateCommonOften dose-dependent; reduce dose if severe.
Peripheral edema (water retention)Mild to ModerateCommonMonitor sodium intake; usually subsides.
Decreased insulin sensitivityModerateUncommonMonitor fasting glucose; consider Berberine.
Carpal tunnel syndromeModerateRareReduce dose or discontinue if symptoms persist.

Contraindications

  • Absolute: Active malignancy, history of cancer, disruption of the hypothalamic-pituitary axis, known hypersensitivity to tesamorelin.
  • Relative: Pre-existing diabetes or severe insulin resistance (requires close monitoring).

Red Flags

Discontinue use and consult a physician if you experience:

  • Fasting blood glucose consistently >100 mg/dL or HbA1c elevation.
  • Severe, persistent joint pain or carpal tunnel symptoms.
  • Signs of hypersensitivity (rash, hives, difficulty breathing).

Pregnancy, Lactation & Fertility

  • Pregnancy: Contraindicated. No adequate human data, but GH axis manipulation is not recommended.
  • Lactation: Unknown if excreted in human milk; use is not recommended.
  • Fertility: No data available.
05 · Common Stacks & Combinations

Common Stacks & Combinations.

Synergistic Stacks

  • Tesamorelin + Ipamorelin: The most common community stack. Tesamorelin (a GHRH) and Ipamorelin (a GHRP) work synergistically to amplify the GH pulse far beyond what either can achieve alone. Typical dose: 1 mg Tesa + 200 mcg Ipa at night. community

Anti-Pattern Stacks (What to Avoid)

StackSeverityRationale
Tesamorelin + Exogenous hGHHighExogenous hGH suppresses endogenous pituitary function, directly neutralizing tesamorelin's mechanism of action.
Tesamorelin + MK-677ModerateBoth strongly stimulate the GH axis; combining them significantly increases the risk of insulin resistance and severe water retention without proportional benefits.
06 · Body Composition & Training Guide

Body Composition & Training Guide.

Expected Trajectory

TimelineExpected Effects
Weeks 1-2Improved sleep quality, vivid dreams, mild water retention.
Weeks 3-6Noticeable improvements in skin elasticity and recovery between workouts.
Weeks 6-12Reduction in visceral adipose tissue, subtle improvements in lean mass.

Training Contexts

  • Fat Loss: Highly effective for targeting stubborn visceral fat when combined with a caloric deficit.
  • Hypertrophy: Provides a supportive environment for muscle growth via elevated IGF-1, but is not a primary driver of massive hypertrophy.
07 · Storage, Handling & Accessibility

Storage, Handling & Accessibility.

  • Unreconstituted (Lyophilized Powder): Store in the refrigerator (2°C to 8°C). Protect from light.
  • Reconstituted: Must be refrigerated (2°C to 8°C).
  • Beyond Use Date (BUD): The FDA label for Egrifta states it should be used immediately after reconstitution. In compounding pharmacy practice, reconstituted tesamorelin is typically considered stable for 14 days when refrigerated. community
  • Accessibility: Available via prescription (Egrifta) or through compounding pharmacies. Banned by WADA for tested athletes.
08 · Bloodwork Monitoring Guide

Bloodwork Monitoring Guide.

Note: Always share peptide usage with your primary care physician. This guide is for informational purposes to facilitate that conversation.

Baseline Panel (Before starting)

  • Fasting Glucose & HbA1c
  • IGF-1 (Insulin-like Growth Factor 1)
  • Comprehensive Metabolic Panel (CMP)
  • Lipid Panel

Mid-Cycle Panel (Week 6-8)

  • Fasting Glucose & HbA1c (Crucial to monitor for insulin resistance)
  • IGF-1 (To verify efficacy and ensure levels aren't excessively supraphysiologic)

Post-Cycle Panel (4 weeks after cessation)

  • Fasting Glucose & HbA1c
  • IGF-1
09 · Comparison to Similar Compounds

Comparison to Similar Compounds.

CompoundPrimary MechanismKey DifferentiatorWhen to Pick
TesamorelinGHRH AnalogueFDA-approved for visceral fat reduction; highly potent.When targeted visceral fat loss is the primary goal and budget allows.
CJC-1295 (No DAC)GHRH AnalogueShorter half-life (30 min); very similar to natural GHRH.For a more natural, pulsatile GH release, usually stacked with a GHRP.
SermorelinGHRH AnalogueThe shortest half-life (10-20 min); the oldest GHRH analogue.For mild anti-aging benefits or those highly sensitive to side effects.
10 · Deep Dive (For Advanced Researchers)

Deep Dive (For Advanced Researchers).

Mechanism of Action

Tesamorelin is a synthetic 44-amino acid peptide that is an analogue of human growth hormone-releasing hormone (GHRH). It binds to and stimulates GHRH receptors in the anterior pituitary gland, leading to the synthesis and pulsatile release of endogenous growth hormone (GH). [5] The addition of a trans-3-hexenoic acid group to the N-terminus of the peptide protects it from degradation by dipeptidyl peptidase-4 (DPP-4), extending its half-life and increasing its potency compared to native GHRH or sermorelin. [1]

Clinical Trial Data

StudyDesignKey Findings
Falutz 2007 [2]Phase 3 RCT (n=412)2 mg/day for 26 weeks decreased visceral adipose tissue by 15.2% and improved lipid profiles in HIV patients.
Stanley 2012 [6]RCT AnalysisReduction in visceral adiposity was associated with improved metabolic profiles.
Stanley 2019 [7]RCT (n=61)Tesamorelin reduced liver fat and prevented progression of fibrosis in HIV-associated NAFLD.
Makimura 2012 [8]RCT (n=60)Tesamorelin reduced visceral fat and improved cognition in obese subjects with reduced GH secretion.

Active Metabolites

Tesamorelin is degraded by proteases in the blood into smaller, inactive peptide fragments. No specific active metabolites have been identified that contribute to its primary pharmacological effects.

Open Questions

  • Long-term cardiovascular outcomes: While tesamorelin improves lipid profiles and reduces visceral fat, long-term studies on hard cardiovascular endpoints (e.g., myocardial infarction, stroke) in non-HIV populations are lacking.
  • Efficacy in non-HIV obesity: While some studies (e.g., Makimura 2012) show promise, large-scale Phase 3 trials for general obesity have not been conducted.
11 · Frequently Asked Questions (FAQ)

Frequently Asked Questions (FAQ).

1. How long does it take to see results from tesamorelin? Improvements in sleep and recovery are often noticed within the first 2 weeks. Changes in body composition, specifically visceral fat reduction, typically take 6 to 12 weeks of consistent use.

2. Does tesamorelin cause insulin resistance? It can. Like all compounds that elevate growth hormone, tesamorelin can decrease insulin sensitivity. Monitoring fasting blood glucose and HbA1c is highly recommended.

3. Can I take tesamorelin if I don't have HIV? While FDA-approved only for HIV-associated lipodystrophy, it is frequently prescribed off-label by anti-aging and wellness clinics for visceral fat reduction and general GH optimization.

4. Why must I inject on an empty stomach? Insulin (released after eating carbohydrates/protein) and somatostatin (released after eating fats) both blunt the release of growth hormone from the pituitary gland, rendering the tesamorelin injection significantly less effective.

5. Is tesamorelin better than exogenous HGH? It is different. Exogenous HGH replaces natural production and can cause pituitary suppression. Tesamorelin stimulates your body to produce its own GH in a natural, pulsatile manner, preserving the feedback loop.

6. Does tesamorelin need to be refrigerated? Yes. Both the lyophilized powder and the reconstituted solution should be stored in the refrigerator (2°C to 8°C) to maintain stability.

7. Can women use tesamorelin? Yes, women can use tesamorelin. However, women generally produce more natural growth hormone than men and may require different dosing strategies. It is contraindicated during pregnancy and lactation.

12 · International Regulatory Status

International Regulatory Status.

Country/RegionRegulatory BodyStatusNotes
United StatesFDAApprovedPrescription only (Egrifta) for HIV lipodystrophy.
United KingdomMHRAUnapprovedNot licensed for medical use.
European UnionEMAUnapprovedEgrifta was withdrawn from the EU market for commercial reasons.
CanadaHealth CanadaApprovedPrescription only (Egrifta).
AustraliaTGARestrictedSchedule 4 (Prescription Only Medicine).
Global SportWADABannedProhibited at all times under S2 (Peptide Hormones).
13 · The Decision Tree

The Decision Tree.

START: Are you a WADA-tested athlete?
├── YES: STOP. Tesamorelin is banned.
└── NO: Do you have an active malignancy or history of cancer?
    ├── YES: STOP. GH secretagogues are contraindicated.
    └── NO: Is your primary goal the reduction of stubborn visceral (belly) fat?
        ├── NO: Consider Ipamorelin or CJC-1295 for general anti-aging.
        └── YES: Are you willing to monitor fasting blood glucose and inject daily?
            ├── NO: Tesamorelin is not a fit.
            └── YES: Tesamorelin is a strong candidate for your protocol.
14 · Schema.org Structured Data

Schema.org Structured Data.

{
  "@context": "https://schema.org",
  "@type": "MedicalEntity",
  "name": "Tesamorelin",
  "alternateName": ["Egrifta", "TH9507"],
  "description": "A synthetic analogue of growth hormone-releasing hormone (GHRH) FDA-approved for the reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "D064426",
      "codingSystem": "MeSH"
    }
  ],
  "legalStatus": {
    "@type": "DrugLegalStatus",
    "applicableLocation": {
      "@type": "Country",
      "name": "US"
    },
    "description": "Prescription Only"
  }
}
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "How long does it take to see results from tesamorelin?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Improvements in sleep and recovery are often noticed within the first 2 weeks. Changes in body composition, specifically visceral fat reduction, typically take 6 to 12 weeks of consistent use."
      }
    },
    {
      "@type": "Question",
      "name": "Does tesamorelin cause insulin resistance?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "It can. Like all compounds that elevate growth hormone, tesamorelin can decrease insulin sensitivity. Monitoring fasting blood glucose and HbA1c is highly recommended."
      }
    },
    {
      "@type": "Question",
      "name": "Can I take tesamorelin if I don't have HIV?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "While FDA-approved only for HIV-associated lipodystrophy, it is frequently prescribed off-label by anti-aging and wellness clinics for visceral fat reduction and general GH optimization."
      }
    },
    {
      "@type": "Question",
      "name": "Why must I inject on an empty stomach?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Insulin and somatostatin both blunt the release of growth hormone from the pituitary gland, rendering the tesamorelin injection significantly less effective."
      }
    },
    {
      "@type": "Question",
      "name": "Is tesamorelin better than exogenous HGH?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "It is different. Exogenous HGH replaces natural production and can cause pituitary suppression. Tesamorelin stimulates your body to produce its own GH in a natural, pulsatile manner."
      }
    },
    {
      "@type": "Question",
      "name": "Does tesamorelin need to be refrigerated?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Both the lyophilized powder and the reconstituted solution should be stored in the refrigerator (2°C to 8°C) to maintain stability."
      }
    },
    {
      "@type": "Question",
      "name": "Can women use tesamorelin?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, women can use tesamorelin. However, women generally produce more natural growth hormone than men and may require different dosing strategies. It is contraindicated during pregnancy and lactation."
      }
    }
  ]
}
15 · References

What we cited.

  1. Cleland, D. A., & Erramouspe, J. (2012). Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 72(14), 1915-1933.
  2. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., ... & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370.
  3. Mangili, A., Falutz, J., Mamputu, J. C., Stepien, M., & Hayward, B. (2011). Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One, 6(10), e26032.
  4. Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy, 46(2), 240-247.
  5. Ferdinandi, C. R., Brazeau, P., & Higham, S. (2007). Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs, 16(7), 1085-1095.
  6. Stanley, T. L., Falutz, J., Marsolais, C., Morin, J., Soulban, G., Mamputu, J. C., ... & Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642-1651.
  7. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., ... & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV, 6(12), e821-e830.
  8. Makimura, H., Feldpausch, M. N., Rope, A. M., Hemphill, L. C., Torriani, M., Lee, H., & Grinspoon, S. K. (2012). Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 97(12), 4769-4779. --- Disclaimer: This document is for informational and harm-reduction purposes only. Tesamorelin is a prescription medication. Always consult a qualified healthcare provider before beginning any peptide protocol.

Track your protocol.

Epti is the first training app built around your peptide protocol.